Oliveira Carla, Westra Jantine L, Arango Diego, Ollikainen Miina, Domingo Enric, Ferreira Ana, Velho Sérgia, Niessen Renee, Lagerstedt Kristina, Alhopuro Pia, Laiho Paivi, Veiga Isabel, Teixeira Manuel R, Ligtenberg Marjolijn, Kleibeuker Jan H, Sijmons Rolf H, Plukker John T, Imai Kohzoh, Lage Pedro, Hamelin Richard, Albuquerque Cristina, Schwartz Simo, Lindblom Annika, Peltomaki Päivi, Yamamoto Hiroyuki, Aaltonen Lauri A, Seruca Raquel, Hofstra Robert M W
Institute of Molecular Pathology and Immunology, The University of Porto, IPATIMUP, 4200-465 Porto, Portugal.
Hum Mol Genet. 2004 Oct 1;13(19):2303-11. doi: 10.1093/hmg/ddh238. Epub 2004 Aug 4.
In sporadic colorectal tumours the BRAFV600E is associated with microsatellite instability (MSI-H) and inversely associated to KRAS mutations. Tumours from hereditary non-polyposis colorectal cancer (HNPCC) patients carrying germline mutations in hMSH2 or hMLH1 do not show BRAFV600E, however no consistent data exist regarding KRAS mutation frequency and spectrum in HNPCC tumours. We investigated KRAS in 158 HNPCC tumours from patients with germline hMLH1, hMSH2 or hMSH6 mutations, 166 MSI-H and 688 microsatellite stable (MSS) sporadic carcinomas. All tumours were characterized for MSI and 81 of 166 sporadic MSI-H colorectal cancer (CRCs) were analysed for hMLH1 promoter hypermethylation. KRAS mutations were observed in 40% of HNPCC tumours, and the mutation frequency varied upon the mismatch repair gene affected: 48% (29/61) in hMSH2, 32% (29/91) in hMLH1 and 83% (5/6) in hMSH6 (P = 0.01). KRAS mutation frequency was different between HNPCC, MSS and MSI-H CRCs (P = 0.002), and MSI-H with hMLH1 hypermethylation (P = 0.005). Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03). HNPCC colorectal and sporadic MSI-H tumours without hMLH1 hypermethylation shared similar KRAS mutation frequency, in particular G13D. In conclusion, we show that depending on the genetic/epigenetic mechanism leading to MSI-H, the outcome in terms of oncogenic activation may be different, reinforcing the idea that HNPCC, sporadic MSI-H (depending on the hMLH1 status) and MSS CRCs, may target distinct kinases within the RAS/RAF/MAPK pathway.
在散发性结直肠癌肿瘤中,BRAFV600E与微卫星不稳定性(MSI-H)相关,而与KRAS突变呈负相关。携带hMSH2或hMLH1种系突变的遗传性非息肉病性结直肠癌(HNPCC)患者的肿瘤未显示BRAFV600E,然而,关于HNPCC肿瘤中KRAS突变频率和谱,尚无一致的数据。我们研究了158例携带hMLH1、hMSH2或hMSH6种系突变的HNPCC肿瘤、166例MSI-H和688例微卫星稳定(MSS)散发性癌中的KRAS情况。所有肿瘤均进行了MSI特征分析,并且对166例散发性MSI-H结直肠癌(CRC)中的81例进行了hMLH1启动子高甲基化分析。在40%的HNPCC肿瘤中观察到KRAS突变,且突变频率因错配修复基因受影响不同而有所变化:hMSH2中为48%(29/61),hMLH1中为32%(29/91),hMSH6中为83%(5/6)(P = 0.01)。HNPCC、MSS和MSI-H CRCs之间的KRAS突变频率不同(P = 0.002),hMLH1高甲基化的MSI-H也不同(P = 0.005)。此外,HNPCC CRCs中G13D突变比MSS更多(P < 0.0001)、比MSI-H更多(P = 0.02),或比hMLH1高甲基化的MSI-H肿瘤更多(P = 0.03)。HNPCC结直肠癌和无hMLH1高甲基化的散发性MSI-H肿瘤具有相似的KRAS突变频率,尤其是G13D。总之,我们表明,取决于导致MSI-H的遗传/表观遗传机制,致癌激活方面的结果可能不同,这强化了以下观点,即HNPCC、散发性MSI-H(取决于hMLH1状态)和MSS CRCs可能靶向RAS/RAF/MAPK途径内不同的激酶。